Long-term patiromer adherence and renin-angiotensin aldosterone system inhibitor utilization: A retrospective study

doi:10.5527/wjn.v15.i1.113599

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-2)

Sum=38

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=26

Mar 25, 2026 (publication date) through Mar 14, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Mar 25, 2026; 15(1): 113599
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.113599

Open in New Tab Full Size Figure Download Figure

Figure 1 Renin-angiotensin-aldosterone system inhibitors subcategory days supply in patients by patiromer adherence. RAASi: Renin-angiotensin-aldosterone system inhibitors; ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; MRA: Mineralocorticoid receptor antagonist; DRi: Direct renin inhibitor; PDC: Proportion of days covered.

Open in New Tab Full Size Figure Download Figure

Figure 2 Average renin-angiotensin-aldosterone system inhibitors subcategory proportion of days covered in patients by patiromer adherence. RAASi: Renin-angiotensin-aldosterone system inhibitors; PDC: Proportion of days covered; ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; MRA: Mineralocorticoid receptor antagonist; DRi: Direct renin inhibitor.

Open in New Tab Full Size Figure Download Figure

Figure 3 Percent of patients with renin-angiotensin-aldosterone system inhibitors subcategory proportion of days covered > 80% by patiromer adherence. RAASi: Renin-angiotensin-aldosterone system inhibitors; PDC: Proportion of days covered; ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; MRA: Mineralocorticoid receptor antagonist; DRi: Direct renin inhibitor.

Citation: Kleinman N, Desai T, Thakar C. Long-term patiromer adherence and renin-angiotensin aldosterone system inhibitor utilization: A retrospective study. World J Nephrol 2026; 15(1): 113599
URL: https://www.wjgnet.com/2220-6124/full/v15/i1/113599.htm
DOI: https://dx.doi.org/10.5527/wjn.v15.i1.113599